Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Oncology

Set Alert for Oncology

Gilead Waives Acquisition Option As Pionyr Explores Other Strategies

Gilead has waived its option to acquire Pionyr, allowing the US biotech to explore other partnerships and financing opportunities as it advances a promising pipeline of macrophage-targeting antibodies.

Deals Cancer

Incyte’s US Approval For PD-1 Inhibitor Zynyz In MCC Draws Muted Response

The US firm’s Zynyz has won accelerated approval for the treatment of first-line Merkel cell carcinoma, bouncing back from a prior regulatory setback, but its third-to-market status leaves it with the crumbs under the table in this orphan indication.

Approvals Companies

Former Seagen CEO Siegall Takes Helm At New Biotech Morphimmune

Siegall is moving on after an unhappy exit from Seagen with a new role at another company with a novel targeted oncology platform.

Leadership Companies

The ChatGPT Revolution Comes To Pharma Business, Starting With Medical Congresses

ChatGPT’s ability to perform sophisticated analysis and writing tasks has taken the world by storm, and now one developer has launched its own AI aimed at revolutionizing pharma’s business intelligence functions.

Companies Artificial Intelligence

Allorion Rides Unconventional Discovery Platforms To Major Funding

Allorion's key innovative attractions include discovery platforms for allosteric inhibitor screening and the discovery of synthetic lethality targets/molecules, along with a small but growing pipeline of novel assets. Founded in 2020, the China- and US-based biotech has now raised more than $100m in three financing deals, including a $50m series B.

China Research & Development

Immuneel COO On Benchmarking The Firm’s CAR-T Against Mature, Global Data Sets

Immuneel’s COO, Dr Arun Anand, talks to Scrip about how things are shaping for the Indian start-up’s autologous CD19 directed CAR-T cell therapy and the ‘journey to be traversed’ on the pricing front. He believes India could potentially see cell therapies being commercialized in the next 12 to 18 months.

Commercial Personalized Medicine

Phase III Results Could Boost Pfizer Revenue Ahead Of Xtandi’s Exclusivity Loss

Pfizer and Astellas announced positive topline Phase III results in non-metastatic prostate cancer for Xtandi, one of the top-selling drugs in Pfizer’s portfolio set to lose patent exclusivity this decade.

Clinical Trials Cancer

Another Blow For Anti-TIGITs As Merck’s Vibostolimab/Keytruda Combo Misses In Phase II NSCLC Trial

Merck & Co’s combination treatment has disappointed in a challenging group of lung cancer patients, marking yet another setback for the increasingly precarious anti-TIGIT space even as some analysts say this is not the end of the road.

Clinical Trials Companies

Scrip Asks…What Does 2023 Hold For Biopharma? Part 8: Therapeutic Area Advances

Neuroscience and oncology fuel high hopes for therapeutic R&D progress among 90-plus surveyed biopharma industry leaders.

Scrip Asks Research & Development

What Seagen’s Pipeline Will Bring To Pfizer

Seagen’s pipeline includes 11 new molecular entities and would double Pfizer’s early-stage oncology clinical pipeline. A next-generation cytotoxic payload for ADCs is on the way too.

Research & Development Cancer

MorphoSys Pins Hopes On Pelabresib For Near-Term Value After Tumultuous 2022

The German biotech has highlighted its myelofibrosis drug candidate, pelabresib, as a key value driver going forward after a year of hard knocks and lackluster Monjuvi sales that forced the firm to downsize its workforce and cease preclinical operations.

Cancer Sales & Earnings

Keen On NASDAQ Slot, Concentra Looks To Scupper Jounce And Redx Merger

In February, Jounce’s future looked bleak after the failure of vopratelimab and fears that its finances would run out. Now, it has two suitors with Concentra making a bid to compete with an all-stock merger with the UK’s Redx.

M & A Business Strategies
See All
UsernamePublicRestriction

Register